^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

thiotepa

i
Other names: DSP-1958
Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor, Alkylating agent
Related drugs:
3d
A Phase II Clinical Study on the Efficacy and Safety of Combination Therapy with Thiotepa, Temozolomide, and Bevacizumab for Recurrent Glioblastoma (ChiCTR2500111976)
P=N/A, N=60, Not yet recruiting, Cancer Hospital of Shandong First Medical University; Cancer Hospital of Shandong First Medical University
New trial
|
Avastin (bevacizumab) • temozolomide • thiotepa
3d
New trial
|
CD34 (CD34 molecule)
|
cytarabine • thiotepa
3d
New P2 trial
|
decitabine • fludarabine IV • thiotepa • busulfan
20d
Trial completion date
|
cytarabine • etoposide IV • carmustine • thiotepa
27d
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) (clinicaltrials.gov)
P2, N=195, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting
Enrollment closed
|
carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa
27d
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
CD34 (CD34 molecule)
|
Chr t(15;17)
|
cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)
1m
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
P1, N=60, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Nov 2027
Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
2ms
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (clinicaltrials.gov)
P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting | Trial completion date: Sep 2032 --> Dec 2032 | Trial primary completion date: Sep 2030 --> Dec 2030
Enrollment open • Trial completion date • Trial primary completion date
|
cisplatin • carboplatin • temozolomide • tamoxifen • cytarabine • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • thiotepa • Neupogen (filgrastim) • celecoxib oral
2ms
New P2 trial
|
cyclophosphamide • thiotepa • busulfan
2ms
New P2 trial
|
Herceptin (trastuzumab) • thiotepa
2ms
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study. (PubMed, Lancet Haematol)
These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies.
P2 data • Preclinical • Journal
|
CD34 (CD34 molecule)
|
cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan